Cinnal-f (follitropin alfa) for Fertility

Cinnal-f is the brand name of follitropin alfa.

In adult women, Cinnal-f is used:

• to help healthy ovaries mature and release an egg
• to help ovaries to make multiple eggs as part of an Assisted Reproductive Technology (ART) program
• together with another medicine called lutropin alfa to help ovulation in women that are not ovulating because their body is producing very little Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH)

In adult men, Cinnal-f is used:

• to help produce sperm in men that are infertile

Do not use Cinnal-f if you:

• are allergic to FSH or any of the other ingredients of this medicine.
• have a tumor in your pituitary or hypothalamus gland.
• have uncontrolled adrenal or thyroid problems

are a woman:

• with ovarian cysts or large ovaries of unknown origin.
• with unexplained vaginal bleeding.
• with cancer in your ovaries, breasts, or womb.
• with a condition that usually makes normal pregnancy impossible, such as ovarian failure (early menopause), or malformed reproductive organs.

are a man:

• with damaged testicles that cannot be healed.

Call your doctor at once if you have diarrhea, nausea, vomiting, abdominal pain or enlargement, oliguria, and dyspnea.

Tell your doctor about all the medicines you take, including prescriptions, vitamins, over-the-counter medicines, and herbal supplements.

• If you use Cinnal-f with medicines that help ovulation (such as clomiphene citrate or hCG), this may increase the response of your follicles.

• If you use Cinnal-f at the same time as a GnRH agonist or antagonist, you may need a higher dose of Cinnal-f to produce follicles.

Your doctor will prescribe the dose that is right for you.

Ovarian cyst, nausea, mastalgia (in men), abdominal pain, upper respiratory tract infection, headache, acne vulgaris, and injection site reaction.

• Ectopic pregnancy: the risk for ectopic pregnancy may be increased in women with tubal abnormalities; intrauterine pregnancy should be confirmed early with hCG testing and transvaginal ultrasound.

• Abortion: the risk of abortion is increased with the use of gonadotropins.

• Ovarian neoplasms: malignant and benign neoplasms have been reported (infrequently) in women receiving multiple-drug therapy for controlled ovarian stimulation.

• Ovarian hyperstimulation syndrome (OHSS): this syndrome may begin within 24 hours of treatment but may become most severe 7 to 10 days after therapy. Symptoms of mild to moderate OHSS may include diarrhea, nausea, abdominal distention/discomfort, and/or vomiting.

• Ovarian enlargement: may be accompanied by abdominal pain or abdominal distention. If ovaries are abnormally enlarged on the last day of treatment, withhold hCG to reduce the risk of OHSS.

• Ovarian torsion: Has been reported following gonadotropin treatment; may be related to OHSS, prior or current ovarian cyst, polycystic ovaries, prior ovarian torsion, pregnancy, or prior abdominal surgery. Early diagnosis may limit the extent of ovarian damage.

• Thromboembolic events: thromboembolic events have been reported.

• Keep Cinnal-f out of the reach of children.

• Do not use it if the solution is leaking, cloudy, or has particles.

• Before you use Cinnal-f pens: store your new Cinnal-f pen in a refrigerator between 2°C and 8°C.

• Do not freeze Cinnal-f and keep away from direct light.

• Store the remaining Cinnal-f pens in the refrigerator between 2°C and 8°C and use them within 4 weeks.

• Do not use any medicine left in your pre-filled pen after 28 days.

• Any unused portion of the Cinnal-f vial should be discarded.